FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2183609787> ?p ?o ?g. }

• W2183609787 endingPage "57" @default.
• W2183609787 startingPage "1348" @default.
• W2183609787 abstract "Fludarabine is an effective therapy for patients with chronic lymphocytic leukemia (CLL) and interferon-alpha (IFN-alpha) has been reported to have anti-leukemic activity in CLL patients. A randomized study was designed to evaluate whether the addition of IFN-alpha to a first-line treatment with fludarabine and prednisone could increase the response rate in patients with advanced CLL and whether IFN-alpha given as maintenance therapy could improve the duration of response.One hundred and thirty-three patients were randomized to receive fludarabine (25 mg/m2/i.v., days 9-13) and prednisone (20 mg/m2, days 1, 3, 5, 7 and 14 and 40 mg/m2, days 9-13) (arm A: 66 patients) or in addition to the same schedule, IFN-alpha (2 MUI/sc, days 1, 3, 5, 7, 9, 11, 13 and 15) (arm B: 67 patients). Seventy-eight patients responsive to therapy entered the post-remission phase of the study in which 41 patients were randomized to receive IFN-alpha (3 MUI three times a week) and 37 to clinical observation.A similar response rate (complete responses + partial responses) was observed in the 2 arms: 86% for arm A and 84% for arm B (p = 0.4). A longer response duration was observed in patients who achieved a complete response (p = 0.001) and in patients who received maintenance therapy with IFN-alpha (p < 0.05). However, the quality of response was the only significant and independent factor influencing response duration (p < 0.01). No benefits in terms of infection-related mortality and morbidity could be ascribed to IFN-alpha administration.In previously untreated CLL patients with advanced disease a high response rate is obtained from first-line fludarabine and prednisone and no benefit is derived from the addition of IFN-alpha to this regimen. The achievement of a good quality response to therapy was the only independent predictor of a prolonged response." @default.
• W2183609787 created "2016-06-24" @default.
• W2183609787 creator A5009095647 @default.
• W2183609787 creator A5021492292 @default.
• W2183609787 creator A5033359713 @default.
• W2183609787 creator A5039006383 @default.
• W2183609787 creator A5039739851 @default.
• W2183609787 creator A5042796311 @default.
• W2183609787 creator A5043649912 @default.
• W2183609787 creator A5044096443 @default.
• W2183609787 creator A5044224344 @default.
• W2183609787 creator A5052387290 @default.
• W2183609787 creator A5067630040 @default.
• W2183609787 date "2003-12-01" @default.
• W2183609787 modified "2023-09-23" @default.
• W2183609787 title "Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study." @default.
• W2183609787 cites W1210631084 @default.
• W2183609787 cites W1271773534 @default.
• W2183609787 cites W1494274243 @default.
• W2183609787 cites W154103547 @default.
• W2183609787 cites W15675347 @default.
• W2183609787 cites W1580788756 @default.
• W2183609787 cites W1638465953 @default.
• W2183609787 cites W1829163682 @default.
• W2183609787 cites W190170648 @default.
• W2183609787 cites W1945274657 @default.
• W2183609787 cites W1979300931 @default.
• W2183609787 cites W1988061664 @default.
• W2183609787 cites W1990158591 @default.
• W2183609787 cites W2028577534 @default.
• W2183609787 cites W2030124997 @default.
• W2183609787 cites W2038252730 @default.
• W2183609787 cites W2045795253 @default.
• W2183609787 cites W2052293974 @default.
• W2183609787 cites W2052908504 @default.
• W2183609787 cites W2062717712 @default.
• W2183609787 cites W2066402887 @default.
• W2183609787 cites W2070193300 @default.
• W2183609787 cites W2077660105 @default.
• W2183609787 cites W2079668255 @default.
• W2183609787 cites W2093434649 @default.
• W2183609787 cites W2123103213 @default.
• W2183609787 cites W2137804513 @default.
• W2183609787 cites W2161926682 @default.
• W2183609787 cites W2289087031 @default.
• W2183609787 cites W2326175431 @default.
• W2183609787 cites W2339387502 @default.
• W2183609787 cites W2339496993 @default.
• W2183609787 cites W2344245690 @default.
• W2183609787 cites W2394823466 @default.
• W2183609787 cites W2396514826 @default.
• W2183609787 cites W2411104373 @default.
• W2183609787 cites W2412731187 @default.
• W2183609787 cites W2418019706 @default.
• W2183609787 cites W2435199713 @default.
• W2183609787 cites W2439205875 @default.
• W2183609787 cites W2466350514 @default.
• W2183609787 cites W2466908410 @default.
• W2183609787 cites W2473009905 @default.
• W2183609787 cites W60865865 @default.
• W2183609787 cites W96780237 @default.
• W2183609787 cites W2471197104 @default.
• W2183609787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14687987" @default.
• W2183609787 hasPublicationYear "2003" @default.
• W2183609787 type Work @default.
• W2183609787 sameAs 2183609787 @default.
• W2183609787 citedByCount "2" @default.
• W2183609787 crossrefType "journal-article" @default.
• W2183609787 hasAuthorship W2183609787A5009095647 @default.
• W2183609787 hasAuthorship W2183609787A5021492292 @default.
• W2183609787 hasAuthorship W2183609787A5033359713 @default.
• W2183609787 hasAuthorship W2183609787A5039006383 @default.
• W2183609787 hasAuthorship W2183609787A5039739851 @default.
• W2183609787 hasAuthorship W2183609787A5042796311 @default.
• W2183609787 hasAuthorship W2183609787A5043649912 @default.
• W2183609787 hasAuthorship W2183609787A5044096443 @default.
• W2183609787 hasAuthorship W2183609787A5044224344 @default.
• W2183609787 hasAuthorship W2183609787A5052387290 @default.
• W2183609787 hasAuthorship W2183609787A5067630040 @default.
• W2183609787 hasConcept C126322002 @default.
• W2183609787 hasConcept C141071460 @default.
• W2183609787 hasConcept C168563851 @default.
• W2183609787 hasConcept C203014093 @default.
• W2183609787 hasConcept C2776178377 @default.
• W2183609787 hasConcept C2776694085 @default.
• W2183609787 hasConcept C2776755627 @default.
• W2183609787 hasConcept C2777938653 @default.
• W2183609787 hasConcept C2778283404 @default.
• W2183609787 hasConcept C2778461978 @default.
• W2183609787 hasConcept C2778720950 @default.
• W2183609787 hasConcept C2779263901 @default.
• W2183609787 hasConcept C2781228144 @default.
• W2183609787 hasConcept C2909179924 @default.
• W2183609787 hasConcept C71924100 @default.
• W2183609787 hasConcept C90924648 @default.
• W2183609787 hasConceptScore W2183609787C126322002 @default.
• W2183609787 hasConceptScore W2183609787C141071460 @default.
• W2183609787 hasConceptScore W2183609787C168563851 @default.

• next